基于网络药理学及分子对接探讨复方扶芳藤合剂治疗慢性肺心病作用机制

打开文本图片集

[关键词］慢性肺心病；复方扶芳藤合剂；网络药理学；分子对接；作用机制[中图分类号］R285 [文献标志码］A [文章编号]0256-7415（2025）12-0187-08DOl：10.13457/j.cnki.jncm.2025.12.035

Exploration of Mechanism of Compound Fufangteng Mixture in Treating Chronic Pulmonary Heart Disease Based on Network Pharmacology and Molecular Docking

HUANG Qingyu1，BAO Yanbo²，LIU Pengye³，HUANG Yewen²，GONG Shengwen1

1.RuikangHospitalAfiliatedtoGuangxi UniversityofChineseMedicine，NanningGuangxi530l1，China；.GuangxiUnivestyof

ChineseMedicine，NanningGuangxi530o01，China；3.TheFirstAflitedHospitalofGuangxiUniversityofChineseMedicine，

Nanning Guangxi 530022，China Abstract：Objective：To explore the mechanism of Compound Fufangteng Mixture in treating chronic pulmonary

heart disease （CPHD）based on network pharmacology and molecular docking.Methods：Active components and

potentialtargets of Compound Fufangteng Mixture were screened using the TCMSPdatabase and HERB website.Disease

targets of CPHD were identified through the GeneCards and OMIM-NCBI databases.Common targets of the drug and

disease were analyzedusing the STRING platform to construct aprotein-protein interaction（PPI）network and identify core targets.GO and KEGG enrichment analyses wereperformed using the DAVID database.Finally，molecular docking was conducted to validate the interactions between five main active componentsand fivecore targets.Results： Network pharmacologyanalysis identified 2O active components in Compound Fufangteng Mixture，including quercetin， kaempferol，7-O-methylisomucronulatol，formononetin，andisorhamnetin.A totalof 186 common targetswere identified between the drug and CPHD，including AKT1，TP53，TNF，JUN，and VEGFA.The common targets were enriched in 2702GO terms and18O pathways，such as the IL-17 signaling pathway，TNF signaling pathway，MAPK signaling pathway，and Th17cell diffrentiation signaling pathway.Molecular docking results showed strong binding affinitiesbetween quercetin and TP53/VEGFA，kaempferol and TP53，and isorhamnetinand VEGFA.Conclusion： Compoud Fufangteng Mixture may treat CPHD through active components such as quercetin，kaempferol，and isorhamnetin acting on core targets and regulating signaling pathways like IL-17，TNF，and MAPK，thereby exerting anti-inflammatory and antioxidant effects.

Keywords：Chronic pulmonary heart disease；Compound Fufangteng Mixture；Network pharmacology; Molecular docking；Mechanism

慢性肺源性心脏病简称慢性肺心病，是由慢性呼吸系统疾病、肺血管病变或胸廓畸形引起肺循环阻力增加，导致肺动脉高压和右心室结构与功能改变的临床综合征，最终可发展为心力衰竭。（剩余7623字）